Ardigen has expanded into immuno-oncology, microbiomics, epigenomics, and CRISPR data analysis to support drug development and precision medicine.
The partners will offer Onegevity's GutBio assay, which integrates metagenomic sequencing with AI-based personalized recommendations to improve gut health, in Japan.
French startup OmicX has built an AI-based search engine for omics-related knowledge to help biomedical researchers find protocols in published literature.
Cambridge Cancer Genomics will contribute AI, liquid biopsy technology, and a TMB sequencing panel to broaden access to cancer immunotherapies in the UK.
Singapore-based Lucence Diagnostics will team with Stanford to analyze sequencing and imaging of liver cancer patients to predict therapeutic effectiveness.
With the acquisition of Swiss healthcare AI specialist SimplicityBio, Precision for Medicine can offer new features in its QuartzBio multiomic data integration platform.
In Science this week: the synthetic genetic system hachimoji, and more.
Emedgene, which makes AI-based, automated genomic interpretation software, will use the Series A funding to expand its US sales operations.
The former cofounder of Knome believes that the future of precision medicine lies in our ability to program living things to act as medicines.
IBM and the Broad Institute will codevelop algorithms to apply artificial intelligence to predict cardiovascular risk from genomic and clinical data.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.
In Nature this week: epigenetic factors that prevent healthy aging and more.